-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

603. Oncogenes and Tumor Suppressors: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
ALL, AML, apoptosis, HSCs, Leukemia, cell division, Diseases, cell regulation, Biological Processes, DNA damage, Technology and Procedures, Cell Lineage, gene editing, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, hematopoiesis, imaging, integrative -omics, molecular interactions, pathogenesis, pathways, signal transduction
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Tiffany Tran, BS1*, Jaspal Bassi2*, Neha Nibber3*, Julia Philipp4*, Jolene Draper4*, Tasha Lin, MD5*, Jayanth Kumar Palanichamy, MD, MBBS6*, Amit Kumar2*, Oscar Silva, MD, PhD7*, May Paing2*, Jennifer King, MD8*, Sol Katzman4*, Jeremy Sanford4* and Dinesh S. Rao, MD, PhD1

1Pathology & Laboratory Medicine, UCLA, Los Angeles, CA
2Pathology & Laboratory Medicine, UCLA, Los Angeles
3UCLA, Los Angeles
4Molecular, Cellular, and Developmental Biology, UCSC, Santa Cruz
5Hematology/Oncology, UCLA, Los Angeles
6All India Institute of Medical Sciences, New Delhi, India
7Department of Pathology, Stanford University Medical Center, Stanford, CA
8Rheumatology, UCLA, Los Angeles, CA

Lisa Marie Kaiser1*, Mirja Harms2*, Jan Münch2* and Christian Buske, MD1

1Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany
2Institute of Molecular Virology, University Hospital Ulm, Ulm, Germany

Boaz Nachmias, MD, PhD1,2*, Veronique Voisin, PhD3*, Geethu Emily Thomas, PhD, MSc, BSc1, Dilshad H. Khan1, Rose Hurren, BSc1*, Aaron Botham4*, Xiaoming Wang1*, Neil Maclean1*, Ayesh K Seneviratne, BSc, MSc1*, Changjiang Xu5*, Jonathan St-Germain1*, Andrea Arruda, MSc6*, Elias Orouji7*, Liran I. Shlush, MD8, Mark D. Minden9, Brian Raught10*, Gary D Bader5* and Aaron D Schimmer, MD, PhD9

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
3Terrence Donnelly Centre for Cellular and Biomedical Research, University of Toronto, Toronto, ON, Canada
4Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
5The Donnelly Centre, University of Toronto, Toronto, ON, Canada
6Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, University of Toronto, Toronto, ON, Canada
7Princess Margaret Cancer Research Centre, Toronto, ON, Canada
8Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
9Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
10Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

Koji Jimbo, MD1*, Takaaki Konuma, MD, PhD1,2*, Takahiro Ito, PhD3*, Yaeko Nakajima-Takagi, PhD4*, Atsushi Iwama, MD, PhD4 and Arinobu Tojo, MD, PhD1,2

1Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
3Laboratory of Cell Fate Dynamics and Therapeutics, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
4Division of Stem Cell and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Bryan T. Ciccarelli, MD, PhD1*, Tinghui Hu, PhD1*, Qing Wang, MD, PhD2*, Julia J. Kim, MD3* and Ian P. Whitehead, PhD1*

1Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ
2Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ
3Rutgers New Jersey Medical School, Newark, NJ

Elyse C Page, BSc1,2*, Susan L Heatley, PhD, MEd1,3,4*, Paul Q Thomas, PhD5,6* and Deborah L White, PhD, FFSc(RCPA)1,2,4,5,7,8

1Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
2School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
3Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia
4Australian and New Zealand Childrens Haematology/Oncology Group (ANZCHOG), Melbourne, Australia
5Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
6Precision Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia
7Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, Australia
8Beat Cancer Project, PRF, SA Cancer Council, Adelaide, Australia

Arpan A. Sinha, MBBS, MD1, Pilar I. Andrade, MS1*, Megan Malone-Perez, BS1*, Syed T Ahmed, MD1* and J. Kimble Frazer, MD, PhD1,2*

1Jimmy Everest Section of Pediatric Hematology/Oncology, Department of Pediatrics, The University of Oklahoma Health Sciences Center, Oklahoma City, OK
2Departments of Cell Biology and Microbiology & Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK

*signifies non-member of ASH